Filing Details

Accession Number:
0001213900-21-009367
Form Type:
13G Filing
Publication Date:
2021-02-16 11:16:57
Filed By:
Nussbaum Ran
Company:
Logicbio Therapeutics Inc. (NASDAQ:LOGC)
Filing Date:
2021-02-16
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Ran Nussbaum 0 1,499,053 0 1,499,053 1,499,053 4.7%
Tomer Kariv 8,033 1,499,053 8,033 1,499,053 1,507,087 4.7%
Pontifax 0 1,499,053 0 1,499,053 1,499,053 4.7%
Pontifax Management IV, G.P. ( 0 1,499,053 0 1,499,053 1,499,053 4.7%
Filing
 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

(Amendment No. 2)

 

(Rule 13d-102)

 

Under the Securities Exchange Act of 1934

 

LogicBio Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

54142F102

(CUSIP Number)

 

February 7, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  Rule 13d-1(b)

 

  Rule 13d-1(c)

 

  Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No. 54142F102 13G Page 2 of 10 Pages

 

1.

Names of Reporting Persons

 

Ran Nussbaum

2.

 

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(See Instructions)

(c) ☐

(d) ☐

 

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

 

Israel

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

1,499,0531

7.

Sole Dispositive Power

 

0 

8.

Shared Dispositive Power

 

1,499,0531

9.

 

 

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,499,0531

10.

 

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

☐ 

11.

 

 

Percent of Class Represented by Amount in Row (9)

 

4.7%

12.

 

 

Type of Reporting Person (See Instructions)

 

IN

 

  1. Consists of: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P.

 

Pontifax 4 G.P., Limited Partnership is the general partner of Pontifax (Israel) IV, Limited Partnership, Pontifax (Cayman) IV, L.P. and Pontifax (China) IV, L.P. Pontifax Management IV, G.P. (2015) Ltd. is the general partner of Pontifax 4 G.P., Limited Partnership. Ran Nussbaum and Tomer Kariv are directors of Pontifax IV, G.P. (2015) Ltd. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

 

 

 

CUSIP No. 54142F102 13G Page 3 of 10 Pages

 

1.

 

Names of Reporting Persons

 

Tomer Kariv

2.

 

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(See Instructions)

(e) ☐

(f) ☐

 

3.

SEC Use Only

 

4.

 

Citizenship or Place of Organization

 

Israel

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

5.

 

 

Sole Voting Power

 

8,0331

6.

 

 

Shared Voting Power

 

1,499,0532

7.

 

 

Sole Dispositive Power

 

8,0331

8.

 

 

Shared Dispositive Power

 

1,499,0532

9.

 

 

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,507,0873

10.

 

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

☐ 

11.

 

 

Percent of Class Represented by Amount in Row (9)

 

4.7%

12.

 

 

Type of Reporting Person (See Instructions)

 

IN

 

1. Consists of options to purchase 8,033 ordinary shares exercisable within 60 days of December 31, 2020.

 

2. Consists of: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P.

 

3. See notes 1 and 2 above.

 

Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

 

 

 

CUSIP No. 54142F102 13G Page 4 of 10 Pages

 

1.

 

 

Names of Reporting Persons

 

Pontifax 4 G.P., Limited Partnership

2.

 

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(See Instructions)

(g) ☐

(h) ☐

 

3.

SEC Use Only

 

4.

 

 

Citizenship or Place of Organization

 

Israel

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

1,499,0531

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

1,499,0531

9.

 

 

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,499,0531

10.

 

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

☐ 

11.

 

 

Percent of Class Represented by Amount in Row (9)

 

4.7%

12.

 

 

Type of Reporting Person (See Instructions)

 

PN

 

1. Consists of: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

 

 

 

CUSIP No. 54142F102 13G Page 5 of 10 Pages

 

1.

 

 

Names of Reporting Persons

 

Pontifax Management IV, G.P. (2015) Ltd.

2.

 

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(See Instructions)

(i) ☐

(j) ☐

 

3.

SEC Use Only

 

4.

 

 

Citizenship or Place of Organization

 

Israel

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

1,499,0531

7.

Sole Dispositive Power

 

0 

8.

Shared Dispositive Power

 

1,499,0531

9.

 

 

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,499,0531

10.

 

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

☐ 

11.

 

 

Percent of Class Represented by Amount in Row (9)

 

4.7%

12.

 

 

Type of Reporting Person (See Instructions)

 

CO

 

1. Consists of: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

 

 

 

CUSIP No. 54142F102 13G Page 6 of 10 Pages

 

Introductory Note: This Schedule 13G is filed on behalf of Pontifax 4 G.P., Limited Partnership, a limited partnership organized under the laws of the State of Israel, Pontifax Management IV, G.P. (2015) Ltd., an Israeli company, Ran Nussbaum and Tomer Kariv (the “Reporting Persons”), in respect of shares of common stock of LogicBio Therapeutics, Inc.

 

Item 1(a). Name of Issuer:

 

LogicBio Therapeutics, Inc. 

 

Item 1(b).

Address of Issuer’s Principal Executive Offices:

 

65 Hayden Avenue, 2nd Floor, Lexington, MA 02421

 

Item 2(a). Name of Person Filing:

 

This Statement is filed on behalf of Pontifax 4 G.P., Limited Partnership, Pontifax Management IV, G.P. (2015) Ltd., Ran Nussbaum. and Tomer Kariv.

 

Item 2(b). Address of Principal Offices or, if None, Residence:

 

The addresses of the Reporting Persons are:

 

Pontifax 4 G.P., Limited Partnership - 14 Shenkar St. Herzliya, 46140, Israel

 

Pontifax Management IV, G.P. (2015) Ltd. – 14 Shenkar St. Herzliya, 46140, Israel

 

Ran Nussbaum - 14 Shenkar St. Herzliya, 46140, Israel

 

Tomer Kariv - 14 Shenkar St. Herzliya, 46140, Israel

 

Item 2(c). Citizenship:

 

Pontifax 4 G.P., Limited Partnership is organized in the State of Israel, Pontifax Management IV, G.P. (2015) Ltd. is incorporated in the State of Israel, Ran Nussbaum is a citizen of the State of Israel, and Tomer Kariv is a citizen of the State of Israel.

 

Item 2(d). Title of Class of Securities:

 

Shares of common stock

 

Item 2(e). CUSIP Number:

 

54142F102

 

 

 

CUSIP No. 54142F102 13G Page 7 of 10 Pages

 

Item 3. If the Statement is being filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the filing person is a:

 

Not applicable.

 

  (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

 

  (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

 

  (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

 

  (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

 

  (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

  (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

  (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

  (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

  (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

 

  (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

  (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                                                           

  

Item 4. Ownership.

 

  (a) Amount beneficially owned:

 

Tomer Kariv: 1,507,087 shares1

Other Reporting Persons: 1,499,053 shares

 

  (b) Percent of class:

 

4.7%1

 

  (c) Number of shares as to which such person has:

 

  (i) Sole power to vote or direct the vote:

 

Tomer Kariv – 8,033 shares

 

 

 

CUSIP No. 54142F102 13G Page 8 of 10 Pages

 

  (ii) Shared power to vote or direct the vote: 1,499,053 shares1

 

  (iii) Sole power to dispose or to direct the disposition of:

 

Tomer Kariv – 8,033 shares

 

  (iv) Shared power to dispose or to direct the disposition of: 1,499,053 shares1

 

1. Includes: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P. In addition, for Mr. Kariv, includes options to purchase 8,033 ordinary shares exercisable within 60 days of December 31, 2020.

 

Pontifax 4 G.P., Limited Partnership is the general partner of Pontifax (Israel) IV, Limited Partnership, Pontifax (Cayman) IV, L.P. and Pontifax (China) IV, L.P. Pontifax Management IV, G.P. (2015) Ltd. is the general partner of Pontifax 4 G.P., Limited Partnership. Ran Nussbaum and Tomer Kariv are directors of Pontifax IV, G.P. (2015) Ltd. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

  

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person had ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certification.

 

Not applicable.

 

 

 

CUSIP No. 54142F102 13G Page 9 of 10 Pages

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 16, 2021
     
PONTIFAX 4 G.P., LIMITED PARTNERSHIP  
     
By: /s/ Pontifax Management IV G.P. (2015) Ltd.  
Name:  Pontifax Management IV G.P. (2015) Ltd.  
Title: General Partner  
     
By: /s/ Ran Nussbaum  
Name: Ran Nussbaum  
Title: Director  
     
PONTIFAX MANAGEMENT IV, G.P. (2015) LTD.  
     
By: /s/ Ran Nussbaum  
Name: Ran Nussbaum  
Title: Director  
     
/s/ Tomer Kariv  
TOMER KARIV  

 

/s/ Ran Nussbaum  
Ran Nussbaum  

 

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

 

 

 

CUSIP No. 54142F102 13G Page 10 of 10 Pages

 

EXHIBIT INDEX

 

A. Joint Filing Agreement, dated as of February 14, 2020, by and among Pontifax 4 G.P., Limited Partnership, Pontifax Management IV, G.P. (2015) Ltd., Ran Nussbaum and Tomer Kariv. (Incorporated by reference from the Schedule 13G filed by the Reporting Persons with respect to the Issuer on February 14, 2020).